secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2025-04-24T23:59:59+00:00
Accession:  0001641172-25-005944
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Cocrystal Pharma's Norovirus Antiviral CDI-988 Shows Potent Activity Against Emerging GII.17 Variants
--------------------------------------------------------------------------------

- CDI-988 demonstrated potent binding to conserved region of GII.17 protease, comparable to activity against GII.4 variants.
- Company plans to initiate a human norovirus challenge study in 2025 for prevention and treatment.
- Phase 1 study showed favorable safety and tolerability of CDI-988 in healthy adults.
- Norovirus causes ~685 million cases and ~50,000 child deaths annually with $60B societal cost.
- No approved antiviral treatments or vaccines for norovirus exist.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225005944/0001641172-25-005944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225005944/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-005944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer